Aristotle Capital Management LLC Has $980.53 Million Stock Holdings in Amgen Inc. $AMGN

Aristotle Capital Management LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,474,491 shares of the medical research company’s stock after selling 153,136 shares during the period. Amgen makes up about 1.9% of Aristotle Capital Management LLC’s portfolio, making the stock its 18th biggest position. Aristotle Capital Management LLC’s holdings in Amgen were worth $980,528,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Evelyn Partners Investment Management LLP acquired a new stake in Amgen in the second quarter valued at about $32,000. Howard Hughes Medical Institute acquired a new position in Amgen during the second quarter worth about $32,000. Cloud Capital Management LLC bought a new position in shares of Amgen in the third quarter worth about $34,000. AXS Investments LLC bought a new position in shares of Amgen in the third quarter worth about $42,000. Finally, Winnow Wealth LLC acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $47,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMGN. Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Citigroup upped their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Guggenheim raised their price objective on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $354.00.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Stock Down 0.4%

NASDAQ:AMGN opened at $366.21 on Friday. The firm’s 50 day simple moving average is $357.73 and its 200 day simple moving average is $325.42. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a market cap of $197.41 billion, a PE ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen’s payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.